PH12013501671A1 - Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate - Google Patents

Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate

Info

Publication number
PH12013501671A1
PH12013501671A1 PH1/2013/501671A PH12013501671A PH12013501671A1 PH 12013501671 A1 PH12013501671 A1 PH 12013501671A1 PH 12013501671 A PH12013501671 A PH 12013501671A PH 12013501671 A1 PH12013501671 A1 PH 12013501671A1
Authority
PH
Philippines
Prior art keywords
beta
methods
methylbutyrate
hydroxy
cognitive function
Prior art date
Application number
PH1/2013/501671A
Other languages
English (en)
Inventor
Ricardo Rueda Cabrera
Maria Ramirez Gonzalez
Manuel Manzano Martin
Jose Maria Lopez Pedrosa
Alejandro Barranco Perez
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PH12013501671A1 publication Critical patent/PH12013501671A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PH1/2013/501671A 2011-02-17 2012-02-13 Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate PH12013501671A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161443762P 2011-02-17 2011-02-17
PCT/US2012/024817 WO2012112419A1 (en) 2011-02-17 2012-02-13 Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate

Publications (1)

Publication Number Publication Date
PH12013501671A1 true PH12013501671A1 (en) 2021-06-02

Family

ID=45757211

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/501671A PH12013501671A1 (en) 2011-02-17 2012-02-13 Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate

Country Status (12)

Country Link
US (1) US9326956B2 (enExample)
EP (1) EP2675298A1 (enExample)
JP (2) JP6034309B2 (enExample)
CN (1) CN103347406B (enExample)
AR (1) AR085297A1 (enExample)
BR (1) BR112013020643A2 (enExample)
CA (1) CA2825734C (enExample)
MX (1) MX348708B (enExample)
PH (1) PH12013501671A1 (enExample)
SG (1) SG192813A1 (enExample)
TW (1) TWI565420B (enExample)
WO (1) WO2012112419A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2481865T3 (es) 2010-01-29 2014-07-31 Abbott Laboratories Emulsiones nutricionales que comprenden HMB de calcio
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
PE20121730A1 (es) 2010-01-29 2013-01-13 Abbott Lab Liquidos nutricionales envasados asepticamente que comprenden beta-hidroxi-beta-metilbutirato (hmb)
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
BR112013020643A2 (pt) 2011-02-17 2016-08-02 Abbott Lab métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato
ES2421187B1 (es) * 2012-02-23 2014-11-26 Abbott Laboratories Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato
EP2745708A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
US20150351438A1 (en) * 2013-01-29 2015-12-10 Otc Nutrition Llc Micronutrient Fortification Delivery
WO2014127112A1 (en) * 2013-02-13 2014-08-21 Baylor College Of Medicine Memory enhancer and actin dynamics
BR112015023316A2 (pt) * 2013-03-15 2017-07-18 Abbott Lab fórmula para bebês de baixa caloria contendo ácido beta-hidroxi-beta-metilbutírico para promover a síntese de proteína e a acreção de massa corporal magra em bebês nascidos a termo
WO2015148982A1 (en) 2014-03-27 2015-10-01 Winterfield Roland W Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
EP3349596B1 (en) * 2015-09-16 2020-04-29 Abbott Laboratories Reduced fat, shelf stable liquid nutritional composition
BR112018009406A8 (pt) * 2015-11-10 2019-02-26 Metabolic Tech Inc ?composição de aditivo de ração, produto de ração, método para prevenir, eliminar e/ou reduzir crescimento microbiano, e, revestimento para um produto de ração animal?
JP7011300B2 (ja) * 2017-12-19 2022-02-10 株式会社島田製薬 ＨＭＢＣａ含有顆粒の製造方法、及びサプリメント

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291525B1 (en) 1999-09-08 2001-09-18 Iowa State University Research Foundation, Inc. Method for improving a human's perception of his emotional state
US7445807B2 (en) 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
US20050027005A1 (en) 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
PL371081A1 (pl) * 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US20060167075A1 (en) 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
EP1973426A2 (en) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
CA2632262C (en) 2005-12-19 2015-04-07 Abbott Laboratories Method of using .beta.-hydroxy-.beta.-methylbutyrate
JP5630750B2 (ja) * 2008-03-18 2014-11-26 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
EP2381784B1 (en) 2008-12-09 2018-07-11 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
JP2009155336A (ja) 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
TW201117736A (en) 2009-11-17 2011-06-01 Hui-Chiang Lu Compositions for sport supplement
CN101785566A (zh) 2010-01-22 2010-07-28 北京康比特体育科技股份有限公司 一种含有hmb的运动饮料
PH12013501292A1 (en) 2010-12-22 2019-03-22 Abbott Lab Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid
CN103269695A (zh) 2010-12-27 2013-08-28 雅培制药有限公司 使用β-羟基-β-甲基丁酸盐促进废用一段时期之后肌肉恢复的方法
BR112013020643A2 (pt) 2011-02-17 2016-08-02 Abbott Lab métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato
HK1205692A1 (en) 2012-03-19 2015-12-24 Abbott Laboratories Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance
WO2014043685A1 (en) 2012-09-17 2014-03-20 Abbott Laboratories Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof

Also Published As

Publication number Publication date
TW201309212A (zh) 2013-03-01
CN103347406B (zh) 2015-08-05
JP2014506890A (ja) 2014-03-20
TWI565420B (zh) 2017-01-11
SG192813A1 (en) 2013-09-30
WO2012112419A8 (en) 2014-03-06
AR085297A1 (es) 2013-09-18
MX348708B (es) 2017-06-26
CA2825734A1 (en) 2012-08-23
BR112013020643A2 (pt) 2016-08-02
JP2017061483A (ja) 2017-03-30
US9326956B2 (en) 2016-05-03
MX2013009528A (es) 2013-10-01
CA2825734C (en) 2016-05-17
US20140249223A1 (en) 2014-09-04
JP6034309B2 (ja) 2016-11-30
JP6340394B2 (ja) 2018-06-06
CN103347406A (zh) 2013-10-09
EP2675298A1 (en) 2013-12-25
WO2012112419A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
PH12013501671A1 (en) Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate
MX2016007492A (es) Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento.
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
NZ708727A (en) Conjugate compounds
WO2013025997A3 (en) Brain stimulation methods for treating central sensitivity
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
PH12013501490A1 (en) Methods for diagnosing and treating eye-length related disorders
AU2018270408A1 (en) Methods of inhibiting aging and treating aging-related disorders
MY179105A (en) Methods of treating alzheimer's disease
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
HK1213291A1 (zh) 用於治療胱氨酸尿症的胱硫醚β合酶
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
MX2019000677A (es) Células miméticas de células b.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
IN2014CN04009A (enExample)
WO2014135878A3 (en) Methods for treating cells with immunosuppressants to enhance their immunosuppressive potency
AU2015362063A8 (en) Compositions and methods for neuronal differentiation of cells